<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181414</url>
  </required_header>
  <id_info>
    <org_study_id>SPARE III - 2010</org_study_id>
    <nct_id>NCT01181414</nct_id>
  </id_info>
  <brief_title>Spanish Atrial Fibrillation And Resynchronization Study</brief_title>
  <acronym>SPAREIII</acronym>
  <official_title>Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarrra Hospital (Clinica Universitaria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare the response to cardiac resynchronization therapy
      (CRT) in patients with chronic advanced heart failure and permanent atrial fibrillation (AF)
      depending on atrio ventricular junction (AVJ) is ablated or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac resynchronization therapy (CRT) improves the functional capacity and the quality of
      life and reduces the mortality of patients with dilated cardiomyopathy, low ejection fraction
      and wide QRS.

      Only 2% of patients included in CRT randomized trials were in AF.

      To obtain a good response to CRT, percentage &gt;90% of ventricular pacing must be obtained.

      Based on observational studies, current guidelines of CRT recommend the atrio ventricular
      junction (AVJ) ablation in those patients with permanent atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular reverse remodelling in cardiac resynchronization therapy and atrial fibrillation.</measure>
    <time_frame>1-year follow-up</time_frame>
    <description>Comparison of echocardiographic responders in patients with permanent atrial fibrillation submitted to cardiac resynchronization therapy depending on whether the atrio-ventricular junction is ablated or not. Echocardiographic response was defined as left ventricular end-systolic volume reduction &gt;10%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response to Cardiac resynchronization therapy.</measure>
    <time_frame>1-year follow-up</time_frame>
    <description>Comparison of clinical response in patients with permanent atrial fibrillation submitted to cardiac resynchronization therapy, depending on whether the atrio-ventricular junction has been ablated or not. Clinical response is defined as not death/heart transplantation and improvement of the distance walked in the 6-minute walking test &gt;10%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrioventricular junction ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrioventricular junction ablation by using radiofrequency energy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug control of ventricular rate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug control of ventricular rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrio ventricular junction ablation with radio-frequency</intervention_name>
    <description>Atrioventricular junction ablation by using radiofrequency energy.</description>
    <arm_group_label>Atrioventricular junction ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker/digoxine/amiodarone</intervention_name>
    <description>Ventricular rate control by using drug treatment.</description>
    <arm_group_label>Drug control of ventricular rate</arm_group_label>
    <other_name>Negative chronotropic drugs pharmacological treatment .</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dilated cardiomyopathy (LVEDD &gt;56 mm)

          -  wide QRS (&gt; 120 msec)

          -  NYHA III-IV

          -  EF&lt;35%

          -  Permanent AF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Tolosana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, University of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Josep Lluis Mont Girbau</investigator_full_name>
    <investigator_title>Head of the Arrhythmia Unit</investigator_title>
  </responsible_party>
  <keyword>Permanent Atrial Fibrillation</keyword>
  <keyword>Resynchronization therapy</keyword>
  <keyword>Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

